drugset / Trial / NCT05961098
A Study of RBD1016 in CHB Participants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a multi-center, randomized, double-blind, placebo-controlled clinical study to assess the safety, efficacy, PK and immunogenicity of RBD1016 injection on NAs background treatment in CHB participants.
Timeline
- Start
- 2023-10-11
- Primary completion
- 2025-04-29
- Completion
- 2025-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RBD1016 | Unknown | 100 mg | Subcutaneous |
| Subject | RBD1016 | Unknown | 200 mg | Subcutaneous |